CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
Perflutren Protein-Type A Microspheres +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05328167
NCT05328167Phase 2Completed

Contrast-Enhanced Ultrasound for Diagnosis and Therapy of Cholangiocarcinoma

Thomas Jefferson University·interventional·Posted Apr 14, 2022·Updated Oct 28, 2025

In Brief

A Phase 2 clinical trial evaluating Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound for Intrahepatic Cholangiocarcinoma. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This phase II trial tests whether contrast-enhanced ultrasound can predict the response of bile duct cancer to targeted radiotherapy (radioembolization treatment). Contrast-enhanced ultrasound uses gas microbubbles that may provide enhancement on ultrasound. It is also possible to pop these microbubbles using ultrasound imaging. Tumors that experience popping of these microbubbles may be easier to kill with radiotherapies. Therefore, this trial may also help doctors see if ultrasound-triggered microbubble popping can improve bile duct cancer response to radiotherapy. Another purpose of this trial is to test if the pressure inside the tumor estimated through ultrasound can be used to predict the tumor response to radiotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedApr 14, 2022
Enrollment StartDec 14, 2021
Primary CompletionJul 31, 2025
Study CompletionAug 31, 2025
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 4.2 years ago

Interventions

Perflutren Protein-Type A Microspheresdrug

Given IV

Contrast-Enhanced Ultrasoundprocedure

Undergo CEUS